SCHEMBL3106901

SCHEMBL3106901

Cc1cc(Cl)ccc1-c1cc(C(Oc2ccc(C(=O)N(C)CCC(=O)O)cc2)C2CCCCC2)c(C)o1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
GCG P01275 3/20 0.34
SLC6A9 P48067 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
HPGD P15428 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GCGR P47871 2/20 0.32
MBTPS1 Q14703 1/20 0.32
KDM1A O60341 1/20 0.32
RCOR1 Q9UKL0 1/20 0.32
LMNA P02545 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
MCHR1 Q99705 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
PTGS2 P35354 2/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102630 0.94 CNR1 (0.35) KDM4EGCGSLC6A9SMN1; SMN2HPGD
SCHEMBL3106617 0.91 OXTR (0.37) KDM4EGCGSLC6A9SMN1; SMN2HPGD
SCHEMBL3091236 0.90 SLC6A9 (0.41) KDM4ESLC6A9SMN1; SMN2NPC1RAB9A
SCHEMBL3109900 0.87 GCG (0.47) GCGSMN1; SMN2HPGDNPC1RAB9A
SCHEMBL3113214 0.86 ACKR3 (0.34) KDM4EGCGSLC6A9GCGR
SCHEMBL3106770 0.86 NR1H4 (0.35) KDM4ESMN1; SMN2HPGDNPC1RAB9A
SCHEMBL13093863 0.86 KDM4E (0.40) KDM4EGCGSLC6A9SMN1; SMN2HPGD
SCHEMBL3110188 0.85 GCG (0.35) GCGSLC6A9SMN1; SMN2GCGRKDM1A
SCHEMBL3098734 0.85 KDM4E (0.39) KDM4EGCGSMN1; SMN2HPGDNPC1
SCHEMBL3091354 0.84 MAPT (0.40) KDM4ESLC6A9HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR KDM4E 2280/4885GCG 11/4885SLC6A9 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.